Kuros Biosciences
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.
Xpand Biotechnology
Acquisition in 2016
Xpand Biotechnology BV, based in Bilthoven, the Netherlands, specializes in technologies for bone repair and regeneration. Founded in 2004 and now a subsidiary of Kuros Biosciences AG, the company develops innovative products utilizing proprietary surface science technology. Xpand Biotechnology offers a bioreactor system that facilitates clinical-scale cell cultivation in a controlled environment, providing an alternative to traditional 2D cell growth methods. Its regenerative medicine initiatives focus on calcium phosphate-based materials that possess osteoconductive properties, supporting bone tissue formation. The company is equipped with research and development, manufacturing, and clean room facilities to advance its mission in regenerative medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.